Ekso Bionics Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Ekso Bionics Holdings wird ein Gewinn- und Umsatzwachstum von 70.7% bzw. 23.9% pro Jahr prognostiziert, während der Gewinn pro Aktie um 71.8% pro Jahr wachsen soll.

Wichtige Informationen

69.3%

Wachstumsrate der Gewinne

71.9%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	16.7%
Wachstumsrate der Einnahmen	23.7%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	24 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.00

May 02

Recent updates

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.00

May 02

Market Still Lacking Some Conviction On Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

Dec 20

Shareholders May Not Be So Generous With Ekso Bionics Holdings, Inc.'s (NASDAQ:EKSO) CEO Compensation And Here's Why

Jun 04

Is Ekso Bionics Holdings (NASDAQ:EKSO) Weighed On By Its Debt Load?

May 26

What Is The Ownership Structure Like For Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)?

Feb 10

Ekso Bionics sees lower 2020 sales vs. 2019

Jan 13

Health Check: How Prudently Does Ekso Bionics Holdings (NASDAQ:EKSO) Use Debt?

Dec 23

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:EKSO - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	36	0	N/A	N/A	1
12/31/2025	28	-5	N/A	N/A	2
12/31/2024	21	-10	N/A	N/A	2
3/31/2024	18	-14	-11	-11	N/A
12/31/2023	18	-15	-12	-12	N/A
9/30/2023	17	-15	-14	-14	N/A
6/30/2023	16	-16	-14	-13	N/A
3/31/2023	14	-15	-15	-15	N/A
12/31/2022	13	-15	-15	-15	N/A
9/30/2022	13	-15	-14	-14	N/A
6/30/2022	13	-12	-14	-14	N/A
3/31/2022	12	-11	-13	-13	N/A
12/31/2021	11	-10	-11	-11	N/A
9/30/2021	9	-11	-10	-10	N/A
6/30/2021	9	-6	-9	-9	N/A
3/31/2021	9	-17	-9	-9	N/A
12/31/2020	9	-16	-9	-9	N/A
9/30/2020	10	-15	-9	-9	N/A
6/30/2020	11	-17	-12	-12	N/A
3/31/2020	12	-8	-12	-12	N/A
12/31/2019	14	-12	-16	-16	N/A
9/30/2019	13	-14	-20	-19	N/A
6/30/2019	13	-21	-19	-19	N/A
3/31/2019	12	-26	-21	-21	N/A
12/31/2018	11	-27	-22	-22	N/A
9/30/2018	10	-32	-23	-23	N/A
6/30/2018	10	-31	-27	-27	N/A
3/31/2018	8	-29	-31	-31	N/A
12/31/2017	7	-29	N/A	-31	N/A
9/30/2017	7	-26	N/A	-30	N/A
6/30/2017	7	-31	N/A	-28	N/A
3/31/2017	7	-35	N/A	-25	N/A
12/31/2016	14	-34	N/A	-25	N/A
9/30/2016	14	-38	N/A	-26	N/A
6/30/2016	15	-31	N/A	-24	N/A
3/31/2016	15	-27	N/A	-21	N/A
12/31/2015	9	-24	N/A	-18	N/A
9/30/2015	8	-35	N/A	-16	N/A
6/30/2015	7	-18	N/A	-15	N/A
3/31/2015	6	44	N/A	-13	N/A
12/31/2014	5	-34	N/A	-15	N/A
9/30/2014	5	-16	N/A	-15	N/A
6/30/2014	4	-30	N/A	-12	N/A
3/31/2014	4	-90	N/A	-12	N/A
12/31/2013	3	-12	N/A	-9	N/A
9/30/2013	3	-13	N/A	-9	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: EKSO wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.4%).

Ertrag vs. Markt: EKSO wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: EKSO wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: EKSODie Einnahmen des Unternehmens (23.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: EKSODie Einnahmen des Unternehmens (23.9% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von EKSO in 3 Jahren voraussichtlich hoch sein wird

Ekso Bionics Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates upgraded to US$0.43 loss, revenue downgraded

Price target increased by 8.1% to US$10.00

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.00

Forecast to breakeven in 2026

Consensus EPS estimates fall by 145%

Price target decreased by 7.5% to US$9.25

Recent updates

Ekso Bionics Holdings, Inc. Appoints Deborah Lafer Scher to its Board of Directors

Consensus EPS estimates upgraded to US$0.43 loss, revenue downgraded

Price target increased by 8.1% to US$10.00

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.00

Forecast to breakeven in 2026

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Ekso Bionics Holdings, Inc., Annual General Meeting, Jun 06, 2024

Ekso Bionics Holdings, Inc. to Report Q1, 2024 Results on Apr 29, 2024

Consensus EPS estimates fall by 145%

Price target decreased by 7.5% to US$9.25

No longer forecast to breakeven

Full year 2023 earnings: EPS misses analyst expectations

Ekso Bionics Holdings, Inc. to Report Q4, 2023 Results on Mar 04, 2024

Consensus estimates of losses per share improve by 26%

Forecast to breakeven in 2026

Ekso Bionics Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $4.6 million.

Ekso Bionics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $4.6 million.

Ekso Bionics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $4.6 million.

Ekso Bionics Holdings, Inc. Launches GaitCoach Software for EksoNR

Ekso Bionics Holdings, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023

Market Still Lacking Some Conviction On Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

Ekso Bionics Holdings, Inc. Receives CMS Coding Approval for Ekso Indego Personal

New major risk - Share price stability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ekso Bionics Holdings, Inc. to Report Q3, 2023 Results on Oct 26, 2023

Ekso Bionics Holdings, Inc. Receives Non-Compliance Notice from Nasdaq

Consensus revenue estimates increase by 12%, EPS downgraded

New major risk - Financial position

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Ekso Bionics Holdings, Inc. to Report Q2, 2023 Results on Jul 27, 2023

New minor risk - Share price stability

Sentiment Still Eluding Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

Executive Chairman of the Board recently sold US$66k worth of stock

Consensus EPS estimates fall by 40%

High number of new and inexperienced directors

No longer forecast to breakeven

Full year 2022 earnings released: US$1.16 loss per share (vs US$0.80 loss in FY 2021)

Forecast to breakeven in 2025

Ekso Bionics Holdings, Inc Announces Director Changes

Ekso Bionics Holdings, Inc. acquired Human Motion and Control Business Unit of Parker Hannifin Corporation for $10 million.

Price target decreased to US$9.00

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Ekso Bionics Holdings, Inc. Approves Appointment of Jerome Wong as Corporate Secretary and Principal Financial Officer

Ekso Bionics Holdings, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Ekso Bionics: Fragile Opportunity

Second quarter 2022 earnings: EPS exceeds analyst expectations

Ekso Bionics Holdings, Inc. to Report Q2, 2022 Results on Jul 28, 2022

Is Ekso Bionics Holdings (NASDAQ:EKSO) A Risky Investment?

Ekso Bionics Holdings, Inc. Receives FDA Clearance to Market Its Eksonr(Tm) Robotic Exoskeleton for Use with Multiple Sclerosis Patients

Ekso Bionics Holdings, Inc. Announces Chief Financial Officer Changes

Ekso Bionics Holdings, Inc., Annual General Meeting, Jun 09, 2022

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$11.00

Ekso Bionics Holdings, Inc. to Report Q1, 2022 Results on Apr 28, 2022

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Ekso Bionics Holdings, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Health Check: How Prudently Does Ekso Bionics Holdings (NASDAQ:EKSO) Use Debt?

Ekso Bionics: Expecting More Of The Same

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.30 profit in 3Q 2020)

Is Ekso Bionics Holdings (NASDAQ:EKSO) Weighed On By Its Debt Load?

Second quarter 2021 earnings released: US$0.10 loss per share (vs US$1.88 loss in 2Q 2020)

Ekso Bionics: Have Robot, Might Travel

Shareholders May Not Be So Generous With Ekso Bionics Holdings, Inc.'s (NASDAQ:EKSO) CEO Compensation And Here's Why

Is Ekso Bionics Holdings (NASDAQ:EKSO) Weighed On By Its Debt Load?

First quarter 2021 earnings released: US$0.34 loss per share (vs US$0.44 loss in 1Q 2020)

Director has left the company

Ekso Bionics Holdings, Inc., Annual General Meeting, Jun 10, 2021

Full year 2020 earnings released: US$2.21 loss per share (vs US$2.53 loss in FY 2019)